Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function.

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised ...

CDR-Life develops highly targeted T cell engagers ... demonstrates the potential of our antibody-derived molecules. Backed by leading cross-Atlantic investors, our team is committed to bringing ...

Portfolio Expansion: CDR111 CDR111, CDR-Life's newest clinical candidate ... AACR Poster Presentation Details Title: A novel T cell engager antibody for the treatment of HLA-A*01/KK-LC-1-positive ...

The program has advanced into Phase 2 (NCT06722157) with patient recruitment now underway. 1 BI 771716, engineered using CDR-Life's proprietary technology and developed by Boehringer Ingelheim, is a ...